항바이러스제 시장 : 예측(2025-2030년)

The Global Anti-Viral Drug market is set to witness robust growth at a CAGR of 4.69% during the forecast period, worth US$ 108.263 billion in 2030 from US$ 86.100 billion in 2025.

Anti-viral drugs are used for treating influenza. When a flu illness develops, anti-viral medications can help reduce fever and flu symptoms such as cough, sore throat, runny or stuffy nose, body aches, headache, chills, and fatigue. The global anti-viral drug market is increasing due to the rising prevalence of influenza across various countries worldwide. The increasing geriatric population across the globe and increasing government initiatives are also among the major factors propelling the growth of the anti-viral drug market during the forecasted timeline.

Market Trends:

• Rising influenza cases globally: The growing number of influenza cases worldwide is a key driver behind the increased demand for anti-viral drugs. The World Health Organization (WHO) reports that seasonal influenza causes 3 to 5 million severe illnesses annually, resulting in 290,000 to 650,000 respiratory-related deaths.
• Increased global vaccine uptake: The expanding use of vaccines worldwide to enhance public health and curb the spread of flu, which has the potential to trigger pandemics, is encouraging governments to intensify efforts in raising awareness about the importance of vaccination.
• North America: North America is poised to hold a substantial portion of the anti-viral drug market, driven by extensive research and development from pharmaceutical companies. This is supported by the presence of major industry players and the region's early adoption of cutting-edge medical treatments.
• Europe: The European market is projected to experience significant growth over the forecast period. This surge is largely fueled by heightened government initiatives focused on advancing research and development for drugs and vaccines.
• Asia Pacific: The Asia Pacific region is anticipated to see rapid growth, primarily due to the rising incidence of influenza and HIV diagnoses. This trend is boosting the use of anti-viral drugs in populous nations such as India and China.

Some of the major players covered in this report F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca plc., AbbVie Inc., Johnson & Johnson, Merck & Co., Inc., Atea Pharmaceuticals, GlaxoSmithKline plc., among others.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Global Anti-Viral Drug Market is analyzed into the following segments:

By Application Type

• Herpes Antiviral Drugs
• Hepatitis Antiviral Drugs
• HIV Antiviral Drugs
• Influenza Antiviral Drugs
• Other Anti-viral Drugs

By Mechanism of Action

• Nucleotide Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Others

By Distribution Channel

• Online
• Offline

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

• 4.1. Product Pipeline
• 4.2. Patent Analysis

5. GLOBAL ANTI-VIRAL DRUG MARKET BY APPLICATION TYPE

• 5.1. Introduction
• 5.2. Herpes Antiviral Drugs
• 5.3. Hepatitis Antiviral Drugs
• 5.4. HIV Antiviral Drugs
• 5.5. Influenza Antiviral Drugs
• 5.6. Other Anti-viral Drugs

6. GLOBAL ANTI-VIRAL DRUG MARKET BY MECHANISM OF ACTION

• 6.1. Introduction
• 6.2. Nucleotide Polymerase Inhibitors
• 6.3. Reverse Transcriptase Inhibitors
• 6.4. Protease Inhibitors
• 6.5. Others

7. GLOBAL ANTI-VIRAL DRUG MARKET BY DISTRIBUTION CHANNEL

• 7.1. Introduction
• 7.2. Online
• 7.3. Offline

8. GLOBAL ANTI-VIRAL DRUG MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Application Type
  • 8.2.2. By Mechanism of Action
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Application Type
  • 8.3.2. By Mechanism of Action
  • 8.3.3. By Distribution Channel
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Application Type
  • 8.4.2. By Mechanism of Action
  • 8.4.3. By Distribution Channel
  • 8.4.4. By Country
    • 8.4.4.1. United Kingdom
    • 8.4.4.2. Germany
    • 8.4.4.3. France
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Application Type
  • 8.5.2. By Mechanism of Action
  • 8.5.3. By Distribution Channel
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Others
• 8.6. Asia Pacific
  • 8.6.1. By Application Type
  • 8.6.2. By Mechanism of Action
  • 8.6.3. By Distribution Channel
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. Japan
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Taiwan
    • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. F. Hoffmann-La Roche Ltd
• 10.2. Gilead Sciences, Inc.
• 10.3. Bristol-Myers Squibb Company
• 10.4. Pfizer Inc.
• 10.5. AstraZeneca plc.
• 10.6. AbbVie Inc.
• 10.7. Johnson & Johnson
• 10.8. Merck & Co., Inc.
• 10.9. Atea Pharmaceuticals
• 10.10. GlaxoSmithKline plc.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations